Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results

Last Modified: 11/7/2006 First Published: 3/1/1999


1.		Phase III Randomized Study of Immunotherapy With Polyvalent Melanoma Vaccine (Canvaxin™) Plus BCG Versus BCG Plus Placebo After Surgery in Patients With Stage IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 to 80				NCI				JWCI-MC-4-001 CV-MMAIT-4-001, RPCI-DS-98-16, NCI-G98-1492, NCT00052156

Last Modified: 11/7/2006 First Published: 12/1/1999


2.		Phase III Randomized Study of BCG Plus a Polyvalent Melanoma Vaccine (Canvaxin™) Versus BCG Plus Placebo in Patients With Resected Stage III Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 to 80				NCI				JWCI-MC-3-001A CV-MMAIT-3-001, NCI-V99-1576, NCT00052130

Last Modified: 3/1/2000 First Published: 1/1/1999


3.		Phase II Randomized Study of Polyvalent Melanoma Vaccine Encapsulated into pH-Sensitive Liposomes in Patients with Stage IIB or III Malignant Melanoma (Summary Last Modified 03/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 75				NCI				NYU-9615 NCI-G98-1488

Last Modified: 6/1/2007 First Published: 11/1/1999


4.		Phase II Randomized Study of Polyvalent Melanoma Vaccine and Interleukin-2 Liposome With or Without One of Two Doses of Interferon alfa-2b in Patients With Stage III Malignant Melanoma (Summary Last Modified 08/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 75				NCI				NYU-9837 NCI-G99-1595, NCT00004104

Last Modified: 6/5/2007 First Published: 8/5/2005


5.		Phase II Study of Polyvalent Melanoma Vaccine (Canvaxin™) in Patients With In-Transit Cutaneous Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 80				Pharmaceutical / Industry				CV-MMAIT-5-001 NCT00128583

Select All on One Page